NEWS & EVENTS

Latest news and upcoming events

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
16 Feb 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Upcoming events
  • ESMO Congress
    9 – 13 September 2022,
    Paris

    download
  • 22nd Annual Biotech in Europe Forum
    21 - 22 September, 2022
    Basel

    download
  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
Laia Crespo joins Ysios Capital Partners as Investment Manager<

Laia Crespo joins Ysios Capital Partners as Investment Manager

Main responsibilities of Laia Crespo will include the identification and assessment of investment and disinvestment opportunities from the scientific and business perspectives

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense<

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.

Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million<

Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million

The fund will be invested in 10 to 12 biotechnology companies in the field of human health.

Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager<

Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager

Main responsibilities of Martín-Ruiz will be to analyze and evaluate the feasibility of the target companies of the fund from a scientific and business point of view.

Paula Olazábal joins Ysios Capital Partners as investment manager<

Paula Olazábal joins Ysios Capital Partners as investment manager

Her appointment comes along with the new stage of the venture capital firm specialized in biotech, which is preparing the first closing of Ysios BioFund I.

Ysios Capital Partners names Marc Casellas as Chief Financial Officer<

Ysios Capital Partners names Marc Casellas as Chief Financial Officer

Ysios has created this position to manage the increased activity expected as the initial capital subscription of its first fund, Ysios BioFund I, draws to a close

Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector<

Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector

The company anticipates a first closing of around EUR 60 million in brief.

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix

Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M.

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix<

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix

The round was led by two of the most experienced life science investors in Europe, LSP (Netherlands) and Ventech (France).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.